Treatability Study Sample Clauses

Treatability Study. If necessary, Respondents shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap). Preliminary (30%) RD. Respondents shall submit a Preliminary (30%) RD for the Project Area for EPA’s comment. All information and activities to be performed under the Preliminary (30%) RD shall be included and updated, as needed, in subsequent RD submittals (i.e., 60%, 95%, and 100%). The Preliminary RD must include: Intermediate (60%) RD. Respondents shall submit the Intermediate (60%) RD for EPA’s comment. The Intermediate RD must: (a) be a continuation and expansion of the Preliminary RD; (b) address EPA’s comments regarding the Preliminary RD; and (c) include the same elements as are required for the Preliminary (30%) RD. Pre-Final (95%) RD. Respondents shall submit the Pre-final (95%) RD for EPA’s comment. The Pre-final RD must be a continuation and expansion of the previous design submittal and must address EPA’s comments regarding the Intermediate RD. The Pre- final RD will serve as the approved Final (100%) RD if EPA approves the Pre-final RD without comments. The Pre-final RD must include: Final (100%) RD. Respondents shall submit the Final (100%) RD for EPA approval. The Final RD must address EPA’s comments on the Pre-final RD and must include final versions of all Pre-final deliverables.
Sample 1Sample 2
AutoNDA by SimpleDocs
Treatability Study. If potential remedial actions involving treatment have been identified by EPA or Respondent, Respondent shall conduct treatability studies, except where the Respondent can demonstrate to EPA’s satisfaction that they are not needed. Respondent shall provide EPA with the following deliverables for review:
Sample 1
Treatability Study. If necessary, Respondents shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap). (a) Respondents shall submit a TS Work Plan (TSWP) for EPA comment and approval. Respondents shall prepare the TSWP in accordance with EPA’s Guide for Conducting Treatability Studies under CERCLA, Final (Oct. 1992), as supplemented for RD by the Remedial Design/Remedial Action Handbook, EPA 540/R-95/059 (June 1995). (b) Following completion of the TS, Respondents shall submit a TS Evaluation Report for EPA comment and approval. (c) EPA may require Respondents to supplement the TS Evaluation Report and/or to perform additional treatability studies.
Sample 1
Treatability Study. If determined necessary by EPA, Respondent shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap).
Sample 1

Related to Treatability Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Corrective Measures If the Participating Generator fails to meet or maintain the requirements set forth in this Agreement and/or the CAISO Tariff, the CAISO shall be permitted to take any of the measures, contained or referenced in the CAISO Tariff, which the CAISO deems to be necessary to correct the situation.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!